Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed advanced malignancy of 1 of the following types:
• * Ovarian cancer
• * All nonmucinous epithelial histologies are eligible
• * Primary peritoneal cavity cancer
• * Fallopian tube cancer
• * Malignant mesothelioma
• * No sarcomatous histology
• * Pancreatic cancer
• * Squamous cell cancer (SCC) of the lung
• * SCC of the cervix
• * SCC of the head and neck
• Recurrent unresectable disease, meeting 1 of the following criteria:
• * Previously treated with definitive standard therapy
• * Patient refused prior standard therapy
• Initial or recurrent tumor positive (at least 30% of tumor cells) for mesothelin by immunohistochemistry\* NOTE: \*Immunohistochemical evaluation not required for patients with pancreatic cancer
• Measurable or evaluable disease
• No clinically significant pericardial effusion
• No known CNS or spinal cord involvement by tumor
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• At least 12 weeks
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 75,000/mm\^3
• Hepatic
• Bilirubin no greater than upper limit of normal (ULN)
• AST and ALT no greater than 2.5 times ULN
• Albumin at least 3.0 g/dL
• Hepatitis B and C negative
• * Seropositive allowed if clinically asymptomatic
• except if clinically asymptomatic and bilirubin and AST and ALT meet the outlined criteria
• Renal
• Creatinine no greater than ULN
• Calcium no greater than ULN
• Cardiovascular
• No New York Heart Association class II-IV cardiovascular disease
• Pulmonary
• Oxygen saturation at least 93% on room air
• DLCO at least 50% of predicted\*
• Total lung capacity and vital capacity at least 50% of predicted\*
• FEV\_1 at least 50% of predicted\* NOTE: \*For patients with pleural mesothelioma and as clinically indicated
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No infection requiring parenteral antibiotics
• No HIV infection
• Serum neutralizing activity to SS1(dsFv)-PE38 immunotoxin (at 200 ng/mL) no greater than 75%
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• Not specified
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• At least 4 weeks since prior therapy and recovered
• No other concurrent antitumor therapy